Skip to main content
. 2020 May 13;9(5):49. doi: 10.1038/s41389-020-0236-x

Fig. 5. Carbidopa decreases AR protein levels via AHR-mediated proteasomal degradation.

Fig. 5

a Immunoblot analysis of AR, PSA, and AHR. LNCaP cells were treated with or without Carbidopa for 24 h. For blocking AHR, CH223191 (10 μM) was added in the experiment as indicated. b Quantitative analysis of each immunoblot; results were normalized to control and data are given as means ± SEM of three independent experiments. *p < 0.05 versus control. #p < 0.05 versus Carbidopa treatment. c LNCaP cells were treated with or without Carbidopa (100 μM). Co-immunoprecipitation assay was used to analyze the interaction between AHR and AR. Immunoprecipitation was done with AR antibody and immunoblot was carried out for AR and AHR. d LNCaP cells were treated with or without Carbidopa (100 μM). CH223191 (10 μM) was co-treated with Carbidopa where indicated. Co-immunoprecipitation assay was used to analyze ubiquitinated AR. Immunoprecipitation was done with AR antibody and immunoblot was carried out for ubiquitin.